USPTO serial 98391336
REGENSKIN
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- HELLMAN, ELI J
- Law office
- TMO LAW OFFICE 131
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with REGENSKIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Jersey City, NJ, US
Jersey City, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lindsay H. Kaplan
PO Box 4062Kingston, NY 12402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for the treatment of wounds, damaged tissue, scars, and skin wrinkles, namely, platelet concentrate, platelet rich plasma, platelet poor plasma, fibrin gel, platelet rich fibrin, cell extracts, cell concentrates, stem cells, hyaluronic acid, silk, chitosan or any combinations thereof; such goods not including implantable medical devices for use in the regeneration of natural tissue | ACTIVE | — |
| 010 | Medical kits comprised primarily of blood collecting tubes, syringes for medical purposes, needles for medical use, connectors for attaching blood collection tubes, centrifuges, syringes, and injection apparatus, nozzles for dispensing biological preparations, stoppers for the sealing of tubes and vials, adapters for connecting syringes to blood collection tubes, transfer devices for the transfer of biological preparations, also including thixotropic gels, anticoagulants, coagulation activating preparations, and hyaluronic acid for pharmaceutical purposes, the aforementioned medical kits intended for the preparation of platelet concentrate, platelet rich plasma, platelet poor plasma, fibrin gel, platelet rich fibrin, cell extracts, cell concentrates, stem cells, hyaluronic acid, silk, chitosan or any combinations thereof; medical kits intended for tissue and cellular regeneration, rejuvenation, healing and repair comprised of receptacles, namely blood collecting and sampling tubes, vials, jars, bags, pouches, cartridges, bottles, cylinders or pods for blood testing apparatus, medical syringes and needles, the aforementioned for regenerative medicine, isolation and application of platelets and cells, for example from blood, fat, bone marrow, stem cells and other tissue; and medical kits comprising blood collecting and sampling tubes for blood testing apparatus, and medical syringes and needles for regenerative medicine, the aforementioned kits for the preparation of a platelet concentrate, the isolation and application of platelets and cells, for example from blood, fat, bone marrow, stem cells and other tissue; such goods not including implantable medical devices for use in the regeneration of natural tissue. | ACTIVE | — |
| 042 | research services, namely, scientific research studies, in the field of tissue and cellular regeneration and rejuvenation, regenerative medicine, isolation and application of a patient's own platelets and cells; Electronic storage services in the nature of database management, namely, electronic storage of business records of others | ACTIVE | — |
| 044 | medical services, namely, treatments using platelet rich plasma, platelet poor plasma, platelet rich fibrin, blood platelet concentrate, platelet fibrin gel, white blood cells, buffy coat, stem cells, and other blood related extracts or any combination of blood contents in the field of tissue and cellular enhancement, repair, reconstruction, regeneration and rejuvenation, regenerative medicine; medical services, namely, treatments using platelet rich plasma, platelet poor plasma, platelet rich fibrin, blood platelet concentrate, platelet fibrin gel, white blood cells, buffy coat, stem cells, and other blood related extracts or any combination of blood contents in the field of blood or bone marrow related components including platelets, plasma concentrates, thrombin serum and stem cells, to mesotherapy, to hyaluronic acid, chitosan or silk, to the isolation, application, micro-needling and/or injection of a patient's own platelets, thrombin serum and/or cells alone or in combination with any other substance including cell extract or cell extracts, stem cells, hyaluronic acid, silk, or chitosan; Providing medical, veterinary and surgical information in the field of tissue and cellular regeneration and rejuvenation, regenerative medicine, isolation and application of a patient's own platelets and cells via the Internet; providing healthcare consultancy and advice for business executives, health care workers, health care specialists, medical doctors and patients in the fields of cellular and tissue regeneration, regenerative medicine, rejuvenation, as well as isolating, treating and injecting blood platelets or cells into patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by REGENLAB USA LLC
- Other trademarks owned by REGENLAB USA LLC
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named REGENSKIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 9, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 8, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 8, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 8, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 2, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 2, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 2, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 10, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 10, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 10, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 23, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 23, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 9, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 5, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 5, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 5, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 28, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 5, 2024 | NWAP | NEW APPLICATION ENTERED | — |